Drug Approval | May 15, 2022
USFDA approves novel, dual-targeted treatment for type 2 diabetes
In clinical trials, treatment proved more effective than other therapies evaluated
In clinical trials, treatment proved more effective than other therapies evaluated
Deucravacitinib is currently under regulatory review in multiple regions, including the U.S., Europe and Japan, and would be the first selective allosteric tyrosine kinase 2 (TYK2) inhibitor approved for the treatment of any disease
The new framework collaboration will support due diligence into ALSA’s potential investments, which will assist with their investment de-risking
To lay a technological foundation for developing exosome-based medicines and cosmetic products for dermatitis treatment
Aims to increase compliance and improve outcomes for People with Diabetes (PwD)
Novel approach driven by GN Corp Japan with potentials in neurological illnesses
Survey findings released in advance of World Lupus Day on May 10
This action makes Veklury the first approved Covid-19 treatment for children less than 12 years of age
The respective expertise of Lonza and Integral Molecular will benefit drug developers in the assessment of the risk for off-target binding and activation
Secretary, Department of Pharmaceuticals and Union Health Secretary Chair a Panel Discussion on the theme 'Indian Pharma Vision 2047'
Subscribe To Our Newsletter & Stay Updated
